UK markets closed

Santhera Pharmaceuticals Holding AG (0QN1.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
8.75+0.24 (+2.77%)
At close: 04:54PM BST
Full screen
Previous close8.52
Bid0.00 x 0
Ask0.00 x 0
Day's range8.75 - 9.27
52-week range5.30 - 14.02
Avg. volume955
Market cap996,060
Beta (5Y monthly)0.58
PE ratio (TTM)N/A
EPS (TTM)-1.62
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update

    Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Revenue from contracts with customers of CHF 3.9 million (H1-2022: CHF 6.3 million)Operating result of CHF -20.3 million (H1-2022: CHF -25.5 million) and net result of CHF -23.3 million (H1-2022: CHF -29.7 million)Review of vamorolone's regulatory filings (NDA, MAA) for Duchenne muscular dystrophy (DMD) treatment proceeding as planned

  • Globe Newswire

    Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group

    Ad hoc announcement pursuant to Art. 53 LR Chiesi Group acquires entire idebenone business including Raxone in Leber's hereditary optic neuropathy (LHON)Chiesi Group assumes French reimbursement liability of EUR 25.3 million from SantheraSanthera retains contingent value for LHON in U.S. and/or other indications worldwideSanthera ceases all Raxone-related activities and intensifies commercial preparation for Duchenne muscular dystrophy candidate vamorolone in Europe Pratteln, Switzerland, July 3

  • Globe Newswire

    Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone

    Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, July 19, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of the exclusive license agreement for vamorolone in North America (NA) with Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), announced on June 20, 2023 [1]. The proceeds from the agreement extend Santhera’s cash reach into 2025. Together with the expected income from ongoing operations, it provides funding for the pre-commercialization and launch of vamorolo